Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. (WeightWatchers), trading under the symbol WW, is frequently in the news for developments in science-backed weight management, clinical programs, and digital health innovation. Company announcements emphasize its role as a global leader in weight health, combining behavioral programs, clinical care, GLP‑1 medications when appropriate, and technology-enabled support.
News about WeightWatchers often covers updates to its integrated GLP‑1 platform, including the WeightWatchers Med+ program and the GLP‑1 Success behavioral support experience. Releases have highlighted access to FDA‑approved GLP‑1 treatments, such as an oral formulation of Wegovy, and the company’s positioning as a NovoCare Recognized Care Provider. These stories focus on how WeightWatchers pairs medication access with evidence‑based nutrition, coaching, and community to improve outcomes.
Investors and observers will also find coverage of new product and feature launches within the WeightWatchers app, such as the Weight Health Score, AI Body Scanner, fitness content partnerships, and configurable Modes that adjust support as members move from weight loss to maintenance. Additional news items include the launch of specialized programs like WeightWatchers for Menopause, the publication of WeightWatchers for Business annual results, collaborations with partners like Amazon Pharmacy, and the introduction of the WeightWatchers Awards for health and wellness products.
On this news page, readers can track earnings announcements, conference participation, leadership appointments, and strategic initiatives related to WeightWatchers’ transformation in the GLP‑1 era. For those following WW stock or the broader weight health sector, the news feed provides a centralized view of how the company is evolving its behavioral and clinical businesses, expanding partnerships, and refining its global weight management platform.
WeightWatchers (NASDAQ: WW) has announced a crucial investor conference call scheduled for May 6, 2025, at 6:00 p.m. ET. During the call, CEO Tara Comonte and CFO Felicia DellaFortuna will discuss an agreement with the company's lenders and noteholders that is expected to lead to a voluntary prepackaged Chapter 11 bankruptcy filing. The agreement aims to significantly reduce WW's debt obligations. The conference call webcast will be available on corporate.ww.com under Events and Presentations, with a replay accessible for at least 90 days.
WeightWatchers has announced a strategic pharmacy integration with LillyDirect's provider Gifthealth to streamline access to Zepbound weight management medication. The partnership enables real-time prescription tracking and simplified fulfillment for WeightWatchers Clinic members through the WeightWatchers App.
Key highlights:
- 33% of WeightWatchers Clinic members currently use Zepbound
- Zepbound vial prescriptions have increased by over 100% in recent months
- A study of 3,260 WeightWatchers Clinic patients showed 21% average body weight loss at 12 months
The integration specifically benefits self-pay patients without insurance coverage by offering Zepbound vials at more affordable prices. This move aligns with WeightWatchers' holistic approach to weight management, combining medication access with their proven behavioral tools and community support system.
WW International reported Q4 2024 results with revenues of $184.4 million and net income of $25.1 million. Total subscribers reached 3.3 million, including 92,000 Clinical subscribers, up 37.8% year-over-year. While subscription revenues declined 7.3%, Clinical subscription revenues grew 57.9% to $20.5 million.
Q4 highlights include improved gross margin of 69.7% (up 906 basis points) and operating income of $36.2 million. The company appointed Tara Comonte as permanent President and CEO.
Full year 2024 showed mixed results with revenues of $785.9 million and a net loss of $345.7 million, including $293.2 million in non-cash impairment charges. The company remains focused on cost management, targeting $100 million in run-rate savings by end of 2025.
WW International (NASDAQ: WW) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025, after market close. The company will host a conference call at 5:00 p.m. ET on the same day.
During the call, Interim President and CEO Tara Comonte and CFO Felicia DellaFortuna will discuss the results and take questions from investors. The webcast will be available on corporate.ww.com under Events and Presentations, with supplemental investor materials provided before the call. A replay will be accessible for approximately 90 days.
WeightWatchers (WW) has launched a next-generation program featuring advanced AI-powered features and expanded nutrition support. The program introduces insurance-covered access to registered dietitians, AI-powered food scanning and recipe analysis tools, and over 150 new ZeroPoint® foods. Key features include personalized nutrition counseling, macro-nutrient tracking, and seamless Points® calculation through photo recognition.
The program complements WW's recent expansion into clinical solutions, including access to weight-loss medications. Studies show members using the Points Program alongside medications achieve 56% more weight loss than those using medications alone. The company reports that members experience a 20% improvement in quality of life with their enhanced model of care.
WW International (NASDAQ: WW) has appointed Felicia DellaFortuna as Chief Financial Officer, effective January 1, 2025, replacing Heather Stark who will depart on December 27, 2024. DellaFortuna brings significant financial leadership experience, having previously served as CFO at Enthusiast Gaming and BuzzFeed, where she drove operational efficiency and profitability. At BuzzFeed, she led key acquisitions including Complex Networks and HuffPost, while diversifying revenue streams. The appointment comes during what the company describes as a critical transformation period as it adapts to rapidly evolving industry conditions.
WW International reported Q3 2024 results with revenues of $192.9 million, down 10.2% year-over-year. The company posted an operating loss of $39.0 million compared to operating income of $30.6 million in the prior year. End of Period Subscribers decreased 8.8% to 3.7 million. Clinical Subscribers grew 71.5% to 78,000. Adjusted gross margin improved to 69.1%. The company recorded non-cash impairment charges of $57.0 million for franchise rights. WW reiterated its full year 2024 guidance, expecting year-end subscribers of at least 3.1 million and revenue of at least $770.0 million.
WW International (NASDAQ: WW) has announced it will release its third quarter 2024 financial results before market open on Wednesday, November 6, 2024. The company will host a conference call at 8:30 a.m. ET on the same day, featuring Interim President and CEO Tara Comonte and CFO Heather Stark, who will discuss the results and address questions from investors. A live webcast will be available on corporate.ww.com, along with supplemental investor materials, and will remain accessible for approximately 90 days.
WeightWatchers (NASDAQ: WW) has announced the addition of compounded semaglutide to its weight management program, starting at $129. This expansion aims to enhance accessibility and affordability of weight loss medications amid ongoing shortages of branded GLP-1 drugs. The company's offering combines clinical interventions with behavioral support, including access to board-certified clinicians, registered dietitians, and the WeightWatchers community.
Key points:
- WeightWatchers partnered with an FDA-registered 503B facility to ensure quality and safety
- The company conducted nearly 3 million stock checks, finding GLP-1 medications in stock only 4.5% of the time
- 45% of eligible WeightWatchers Clinic members were denied insurance coverage for GLP-1 medications
- Members using GLP-1 medications with the Points® Program lose 11% more weight than those using medications alone
- Compounded semaglutide will be available to eligible members within 1-3 business days